A July 2026 JCAD review lays out a three-phase plan to prevent and manage GLP-1 facial aging using biostimulators, fillers, energy devices, and fat grafting.
A July 2026 Journal of Clinical and Aesthetic Dermatology review maps a three-phase plan for GLP-1 facial aging: at drug initiation, tighten skin with energy devices; during active weight loss, replace volume with biostimulators and HA fillers every few kilograms; after reaching goal weight, maintain results with fat grafting and microneedling.
Rapid weight loss from GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), all FDA-approved for type 2 diabetes or chronic weight management, is increasingly linked to a gaunt, hollowed facial appearance popularly called Ozempic face. A peer-reviewed review published July 1, 2026 in the Journal of Clinical and Aesthetic Dermatology sets out a structured, staged framework for preventing and correcting these changes. Facial aging is not an approved indication for these drugs. It is a secondary effect of the facial fat loss they produce, and the review is guidance built on clinical experience rather than a treatment mandate.
Authors Kanthi Bommareddy, MD, Sabrina Fabi, MD, and Mariana Muniz, MD, describe GLP-1 related weight loss thinning three layers of facial fat, with reported reductions such as roughly 70 percent in cheek fat pads and up to 41.8 percent in superficial temporal fat pads. They propose a three-phase, multimodal plan. At drug initiation (Time Zero), the focus is skin quality without added volume: microfocused ultrasound, fractional lasers, and topical peptides and polynucleotides. During active weight loss, roughly every 4 to 5 kg lost, clinicians address evolving volume deficits with collagen-stimulating injectables such as calcium hydroxyapatite and poly-L-lactic acid (both FDA-approved biostimulators), hyaluronic acid fillers (FDA-approved) for residual hollows, and neuromodulators (FDA-approved) where indicated. After goal weight, maintenance every 6 to 12 months may use multilayer fat grafting, continued skin tightening, and radiofrequency microneedling. The authors also stress adequate protein and micronutrients to support tissue repair.
An estimated 13 percent of US adults have used a GLP-1 drug, and demand for facial correction is rising in step. A separate systematic review in Aesthetic Surgery Journal Open Forum (June 2025) found significant weight loss can leave patients looking up to five years older, with fat loss across temples, cheeks, tear troughs, and jawline. A December 2025 review in the Journal of Clinical Medicine reported about 65 percent of GLP-1 patients noticing facial volume loss and estimated a 7 percent midface volume loss for every 10 kg dropped. A shared theme across all three papers is timing: volumizing and surgical work is generally best sequenced around, not against, ongoing weight loss, and ideally once weight has stabilized.
The evidence base is thin. The JCAD authors note few large randomized trials of regenerative aesthetics in GLP-1 patients, so recommendations rest on existing data and expert practice. Not every tool in the protocol carries the same regulatory footing: topical and injectable polynucleotides are not FDA-approved for aesthetic use in the US and evidence remains limited, while platelet-rich plasma and platelet-rich fibrin are autologous preparations used off-label for facial rejuvenation. Fat grafting is a surgical procedure with its own risks. Cost and access are real barriers, and GLP-1 associated delayed gastric emptying can raise anesthesia considerations for any surgical option. Anyone weighing treatment should discuss sequencing and candidacy with a qualified, licensed provider rather than self-directing a plan.